Victrex plc (LON:VCT) has received a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is GBX 2,169.17 ($28.53).
A number of research analysts have issued reports on VCT shares. Barclays lowered their price objective on Victrex from GBX 2,020 ($26.57) to GBX 1,940 ($25.52) and set an “equal weight” rating for the company in a research note on Wednesday, November 27th. Stifel Nicolaus cut Victrex to a “hold” rating and lowered their price objective for the company from GBX 2,255 ($29.66) to GBX 2,125 ($27.95) in a research note on Friday, September 27th. Peel Hunt reiterated a “hold” rating on shares of Victrex in a research note on Thursday, December 5th. Credit Suisse Group reiterated an “outperform” rating on shares of Victrex in a research note on Tuesday, November 12th. Finally, UBS Group reiterated a “neutral” rating on shares of Victrex in a research note on Friday, December 6th.
LON:VCT traded up GBX 42 ($0.55) during trading hours on Monday, reaching GBX 2,448 ($32.20). 538,672 shares of the company traded hands, compared to its average volume of 274,177. The business’s 50-day moving average price is GBX 2,332.24 and its two-hundred day moving average price is GBX 2,124.99. The stock has a market capitalization of $2.12 billion and a P/E ratio of 21.29. Victrex has a 1 year low of GBX 1,813.68 ($23.86) and a 1 year high of GBX 2,544 ($33.46).
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Featured Article: Yield Curve
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.